Construction of a Pyroptosis-Related Genes Signature to Improve the Prognostic Prediction and Therapeutic Drugs Selection in Patients with Pancreatic Cancer

Changjuan Li,1,2 Min Wang,3 Junwei Wei,2 Wenjuan Zhang,2 Haitao Liu,2 Dongqiang Zhao1 1Department of Gastroenterology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei Province, People’s Republic of China; 2Department of Gastroenterology, The First Hospital of Handan City, Handan...

Full description

Bibliographic Details
Main Authors: Li C, Wang M, Wei J, Zhang W, Liu H, Zhao D
Format: Article
Language:English
Published: Dove Medical Press 2022-08-01
Series:International Journal of General Medicine
Subjects:
Online Access:https://www.dovepress.com/construction-of-a-pyroptosis-related-genes-signature-to-improve-the-pr-peer-reviewed-fulltext-article-IJGM
_version_ 1811345170881314816
author Li C
Wang M
Wei J
Zhang W
Liu H
Zhao D
author_facet Li C
Wang M
Wei J
Zhang W
Liu H
Zhao D
author_sort Li C
collection DOAJ
description Changjuan Li,1,2 Min Wang,3 Junwei Wei,2 Wenjuan Zhang,2 Haitao Liu,2 Dongqiang Zhao1 1Department of Gastroenterology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei Province, People’s Republic of China; 2Department of Gastroenterology, The First Hospital of Handan City, Handan, Hebei Province, People’s Republic of China; 3Department of Anorectal Surgery, The First Hospital of Handan City, Handan, Hebei Province, People’s Republic of ChinaCorrespondence: Dongqiang Zhao, Department of Gastroenterology, The Second Hospital of Hebei Medical University, No. 215, He ping West Road, Xinhua District, Shijiazhuang, Hebei, People’s Republic of China, Email hbzdq1998@163.comBackground: Effective prognostic assessment and appropriate drug selection are important for the clinical management of pancreatic cancer (PaC). Here, we aimed to establish a pyroptosis-associated genes (PRGs) signature to predict the prognostic outcomes of PaC and guide clinical drug therapy.Methods: We identified the differentially expressed PRGs between pancreatic adenocarcinoma (n = 178) and control pancreas samples (n = 171) obtained from different databases, and performed Lasso and Cox regression analysis to create a prognosis signature. Kaplan–Meier (K-M) survival curves and time-dependent receiver operating characteristics were further constructed to assess the utility of the risk model. The International Cancer Genome Consortium (ICGC) PACA-AU cohort (n = 95) was used as a validation dataset to examine the validity of this prognostic model. The correlations of risk score (RS) with clinical features, immune cell infiltration, tumor mutation burden and half-maximal inhibitory concentrations (IC50) of chemotherapeutic drugs were analyzed, and the expression levels of PRGs in cell lines were detected.Results: A prognostic signature was constructed, which consisted of 4 PRGs (AIM2, IL18, GSMDC and PLCG1). K-M analysis demonstrated a remarkable difference in overall survival (OS) time between low-risk (LR) and high-risk (HR) groups (P < 0.001). The RS contributed to the progression of PaC, and could be a significant independent factor for prognostic prediction. The validation of the ICGC cohort confirmed the effectiveness of the proposed signature. The patients with a HR score in the TCGA cohort had higher tumor mutation burden and more sensitivity to paclitaxel, gemcitabine, 5-fluorouracil and cisplatin than those with a LR score. The differential expression levels of signature genes were verified in vitro.Conclusion: The PRGs signature can be applied for predicting the prognosis of PaC, and may provide useful information for selection of therapeutic drugs.Keywords: pancreatic cancer, pyroptosis-related genes, TCGA, prognosis, bioinformatics analysis, tumor mutation burden
first_indexed 2024-04-13T20:00:24Z
format Article
id doaj.art-5e4495ba8d074521825fb8214b2f7c6c
institution Directory Open Access Journal
issn 1178-7074
language English
last_indexed 2024-04-13T20:00:24Z
publishDate 2022-08-01
publisher Dove Medical Press
record_format Article
series International Journal of General Medicine
spelling doaj.art-5e4495ba8d074521825fb8214b2f7c6c2022-12-22T02:32:14ZengDove Medical PressInternational Journal of General Medicine1178-70742022-08-01Volume 156387640377004Construction of a Pyroptosis-Related Genes Signature to Improve the Prognostic Prediction and Therapeutic Drugs Selection in Patients with Pancreatic CancerLi CWang MWei JZhang WLiu HZhao DChangjuan Li,1,2 Min Wang,3 Junwei Wei,2 Wenjuan Zhang,2 Haitao Liu,2 Dongqiang Zhao1 1Department of Gastroenterology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei Province, People’s Republic of China; 2Department of Gastroenterology, The First Hospital of Handan City, Handan, Hebei Province, People’s Republic of China; 3Department of Anorectal Surgery, The First Hospital of Handan City, Handan, Hebei Province, People’s Republic of ChinaCorrespondence: Dongqiang Zhao, Department of Gastroenterology, The Second Hospital of Hebei Medical University, No. 215, He ping West Road, Xinhua District, Shijiazhuang, Hebei, People’s Republic of China, Email hbzdq1998@163.comBackground: Effective prognostic assessment and appropriate drug selection are important for the clinical management of pancreatic cancer (PaC). Here, we aimed to establish a pyroptosis-associated genes (PRGs) signature to predict the prognostic outcomes of PaC and guide clinical drug therapy.Methods: We identified the differentially expressed PRGs between pancreatic adenocarcinoma (n = 178) and control pancreas samples (n = 171) obtained from different databases, and performed Lasso and Cox regression analysis to create a prognosis signature. Kaplan–Meier (K-M) survival curves and time-dependent receiver operating characteristics were further constructed to assess the utility of the risk model. The International Cancer Genome Consortium (ICGC) PACA-AU cohort (n = 95) was used as a validation dataset to examine the validity of this prognostic model. The correlations of risk score (RS) with clinical features, immune cell infiltration, tumor mutation burden and half-maximal inhibitory concentrations (IC50) of chemotherapeutic drugs were analyzed, and the expression levels of PRGs in cell lines were detected.Results: A prognostic signature was constructed, which consisted of 4 PRGs (AIM2, IL18, GSMDC and PLCG1). K-M analysis demonstrated a remarkable difference in overall survival (OS) time between low-risk (LR) and high-risk (HR) groups (P < 0.001). The RS contributed to the progression of PaC, and could be a significant independent factor for prognostic prediction. The validation of the ICGC cohort confirmed the effectiveness of the proposed signature. The patients with a HR score in the TCGA cohort had higher tumor mutation burden and more sensitivity to paclitaxel, gemcitabine, 5-fluorouracil and cisplatin than those with a LR score. The differential expression levels of signature genes were verified in vitro.Conclusion: The PRGs signature can be applied for predicting the prognosis of PaC, and may provide useful information for selection of therapeutic drugs.Keywords: pancreatic cancer, pyroptosis-related genes, TCGA, prognosis, bioinformatics analysis, tumor mutation burdenhttps://www.dovepress.com/construction-of-a-pyroptosis-related-genes-signature-to-improve-the-pr-peer-reviewed-fulltext-article-IJGMpancreatic cancerpyroptosis-related genestcgaprognosisbioinformatics analysistumor mutation burden
spellingShingle Li C
Wang M
Wei J
Zhang W
Liu H
Zhao D
Construction of a Pyroptosis-Related Genes Signature to Improve the Prognostic Prediction and Therapeutic Drugs Selection in Patients with Pancreatic Cancer
International Journal of General Medicine
pancreatic cancer
pyroptosis-related genes
tcga
prognosis
bioinformatics analysis
tumor mutation burden
title Construction of a Pyroptosis-Related Genes Signature to Improve the Prognostic Prediction and Therapeutic Drugs Selection in Patients with Pancreatic Cancer
title_full Construction of a Pyroptosis-Related Genes Signature to Improve the Prognostic Prediction and Therapeutic Drugs Selection in Patients with Pancreatic Cancer
title_fullStr Construction of a Pyroptosis-Related Genes Signature to Improve the Prognostic Prediction and Therapeutic Drugs Selection in Patients with Pancreatic Cancer
title_full_unstemmed Construction of a Pyroptosis-Related Genes Signature to Improve the Prognostic Prediction and Therapeutic Drugs Selection in Patients with Pancreatic Cancer
title_short Construction of a Pyroptosis-Related Genes Signature to Improve the Prognostic Prediction and Therapeutic Drugs Selection in Patients with Pancreatic Cancer
title_sort construction of a pyroptosis related genes signature to improve the prognostic prediction and therapeutic drugs selection in patients with pancreatic cancer
topic pancreatic cancer
pyroptosis-related genes
tcga
prognosis
bioinformatics analysis
tumor mutation burden
url https://www.dovepress.com/construction-of-a-pyroptosis-related-genes-signature-to-improve-the-pr-peer-reviewed-fulltext-article-IJGM
work_keys_str_mv AT lic constructionofapyroptosisrelatedgenessignaturetoimprovetheprognosticpredictionandtherapeuticdrugsselectioninpatientswithpancreaticcancer
AT wangm constructionofapyroptosisrelatedgenessignaturetoimprovetheprognosticpredictionandtherapeuticdrugsselectioninpatientswithpancreaticcancer
AT weij constructionofapyroptosisrelatedgenessignaturetoimprovetheprognosticpredictionandtherapeuticdrugsselectioninpatientswithpancreaticcancer
AT zhangw constructionofapyroptosisrelatedgenessignaturetoimprovetheprognosticpredictionandtherapeuticdrugsselectioninpatientswithpancreaticcancer
AT liuh constructionofapyroptosisrelatedgenessignaturetoimprovetheprognosticpredictionandtherapeuticdrugsselectioninpatientswithpancreaticcancer
AT zhaod constructionofapyroptosisrelatedgenessignaturetoimprovetheprognosticpredictionandtherapeuticdrugsselectioninpatientswithpancreaticcancer